Home / Business and Economy / Digital Health Giant Turns EBITDA Positive
Digital Health Giant Turns EBITDA Positive
27 May
Summary
- Diagnostics business reached ₹600 crore annualized revenue run rate.
- ePharmacy segment achieved breakeven and special pharma grew 65%.
- All core businesses turned EBITDA positive in December 2025.
Tata 1mg has achieved a significant milestone, with all its core businesses turning EBITDA positive in December 2025 and maintaining this momentum through the fourth quarter of FY26. This marks a pivotal moment for the integrated digital healthcare platform.
The diagnostics business has crossed an annualized revenue run rate exceeding ₹600 crore, demonstrating over 40% year-on-year growth. Meanwhile, the ePharmacy segment, ranked number one in India, has reached breakeven, expanding its reach with express delivery available in 10 cities.
The Speciality Pharma business experienced substantial growth of approximately 65% in FY26. Additionally, its direct-to-consumer health products business surpassed ₹200 crore in ARR while remaining profitable. The company is also expanding its offline retail presence, aiming for over 500 stores within the next 12 months.
Investing further in AI, Tata 1mg's insights platform, Pulse, is utilized by over 75 pharmaceutical companies. Future growth strategies include faster pharmacy deliveries, diagnostics expansion into radiology, and AI-driven personalization to solidify its vision of becoming India's most trusted omnichannel healthcare platform.
